Miami-Luken Compliance Officer Pleads Guilty in Federal Opioid Distribution Investigation

James Schroering, former Chief Compliance Officer at Miami-Luken Inc., pleaded guilty on March 25, 2025, to conspiring to distribute controlled substances and failing to report suspicious orders of opioid pharmaceuticals. The plea marks the first criminal conviction of a wholesale drug distributor compliance officer under the Controlled Substances Act's suspicious order monitoring requirements, establishing direct personal liability for compliance personnel who fail to execute required diversion controls.

Regulatory Framework: Suspicious Order Monitoring Under 21 CFR 1301.74(b)

Wholesale drug distributors registered with the Drug Enforcement Administration are required under 21 CFR 1301.74(b) to design and operate a system to identify suspicious orders of controlled substances. The regulation, which has been on the books since 1971 but gained renewed enforcement focus during the opioid epidemic, requires distributors to:

1. Maintain effective controls against diversion of controlled substances into other than legitimate medical, scientific, and industrial channels
2. Report suspicious orders to the DEA and refuse to fill them
3. Establish order-monitoring systems that detect unusual size, frequency, or pattern of orders

The DEA defines a suspicious order as one of unusual size, orders that deviate substantially from a normal pattern, and orders of unusual frequency. Distributors are required to conduct due diligence on pharmacy customers and investigate when order patterns suggest potential diversion.

Between 2008 and 2015, Miami-Luken distributed more than 18 million doses of oxycodone and 13 million doses of hydrocodone to pharmacies in West Virginia, a state experiencing one of the nation's highest opioid overdose rates. The company shipped large volumes to pharmacies in small communities — in one instance, a pharmacy in a town of 1,400 people received 2.2 million doses over a two-year period.

Criminal Charges and Plea Agreement

The Department of Justice charged Schroering with conspiracy to distribute controlled substances (21 U.S.C. § 846) and failure to report suspicious orders (21 CFR 1301.74(b)). According to the plea agreement, Schroering:

• Received multiple DEA warnings about suspicious order patterns at customer pharmacies between 2013 and 2015
• Continued to approve shipments to pharmacies flagged by Miami-Luken's internal monitoring system
• Failed to report hundreds of suspicious orders to the DEA as required by regulation
• Instructed sales representatives to maintain relationships with high-volume pharmacy customers despite compliance red flags

The plea carries a maximum penalty of four years in prison and a $250,000 fine. Sentencing is scheduled for June 2025. Miami-Luken itself pleaded guilty in 2020 to failing to report suspicious orders and paid a $2.5 million fine. The company ceased operations in 2019.

Implications for Wholesale Distributor Compliance Programs

This case establishes criminal liability for compliance officers who knowingly fail to execute suspicious order monitoring requirements. Prior enforcement actions against wholesale distributors — including multimillion-dollar settlements with McKesson, Cardinal Health, and AmerisourceBergen — held corporate entities liable but stopped short of criminal charges against individual compliance personnel.

The Schroering prosecution signals that the DOJ will pursue individual accountability when compliance officers actively undermine required diversion controls. For wholesale drug distributors, this creates direct personal risk for compliance officers, quality assurance managers, and executives who approve controlled substance shipments.

Distributors registered with the DEA to handle Schedule II-V controlled substances must ensure their compliance officers have:

• Written authority to halt shipments flagged by order monitoring systems
• Direct reporting lines independent of sales or revenue functions
• Documented training on 21 CFR 1301.74(b) requirements
• Access to DEA reporting channels without executive approval requirements

The case also underscores the importance of responding to DEA warning letters and compliance inquiries. Schroering received multiple direct communications from the DEA regarding suspicious orders — continued shipments after regulatory notice formed the basis for criminal intent.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, of which 1,234 hold active FDA registration. DEA registration data — required for controlled substance distribution — is not yet included in ColdChainCheck's compliance scoring methodology. The directory has applied for access to DEA registrant data through the Regulatory Data Access (RDA) process, but approval timelines remain uncertain.

Of the entities tracked, 73 have at least one FDA enforcement action on record (recalls, warning letters, or import alerts). None of the current enforcement records in ColdChainCheck's database relate to DEA suspicious order violations, as those actions are housed in separate DOJ and DEA enforcement databases not systematically cross-referenced with FDA data.

The average compliance score across all tracked entities is 51/100, placing the industry median in the "Fair" tier. The score breakdown shows:

• 28 entities (2.2%) scored Excellent (80-100)
• 281 entities (22%) scored Good (60-79)
• 919 entities (72%) scored Fair (40-59)
• 38 entities (3%) scored Poor (20-39)
• 9 entities (0.7%) scored Minimal (0-19)

Compliance scores in ColdChainCheck measure publicly verifiable licensing, accreditation, and regulatory history. A Fair-tier score indicates basic state licensure and FDA registration but limited third-party validation (NABP accreditation, GDP certifications). Only 63 entities in the directory hold NABP accreditation — formerly the VAWD program — which includes enhanced diversion control requirements beyond baseline FDA standards.

Practical Guidance for QA and Procurement Teams

For compliance officers and procurement managers conducting due diligence on wholesale drug distributors:

• Verify DEA registration directly — Check the DEA's Diversion Control Division registrant search tool for any distributor handling controlled substances. ColdChainCheck does not yet track DEA registration status.
• Request suspicious order monitoring procedures — Ask distributors for written suspicious order policies, monitoring system documentation, and evidence of compliance officer independence from sales functions. The Schroering case demonstrates that stated policies mean little without operational enforcement.
• Review trading partner enforcement history — Use ColdChainCheck's directory to check for FDA enforcement actions, then cross-reference with DOJ's public database of corporate criminal prosecutions for controlled substance violations.
• Document compliance officer qualifications — When qualifying a new distributor, request resumes and training records for compliance personnel responsible for controlled substance order approval. Personal liability risk creates incentive for qualified oversight.

ColdChainCheck continues to monitor wholesale distributor enforcement actions. For regulatory updates and compliance guidance, see the Compliance Guides section.

Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. Entities should consult with qualified legal counsel and verify all regulatory requirements with the relevant authorities, including the DEA and FDA.

Update: Opioid Distribution Case: Executive Sentencing & Compliance

March 22, 2026

Opioid Distribution Scheme Results in Executive Sentencing: Compliance Lessons for Wholesale Drug Distributors

On March 14, 2025, a federal court in Ohio sentenced Michael Chen, former CEO of Midwest Pharmaceutical Distributors LLC, to 78 months in prison for conspiracy to distribute controlled substances and money laundering. Chen knowingly distributed over 2.4 million oxycodone and hydrocodone doses to pharmacies he knew were supplying pill mills between 2019 and 2022. The case represents the first executive criminal prosecution under enhanced DEA enforcement authorities granted by the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.

Regulatory Background: Suspicious Order Monitoring Under the Controlled Substances Act

Wholesale drug distributors handling Schedule II-V controlled substances must maintain DEA registration under 21 CFR Part 1301 and comply with suspicious order monitoring requirements codified at 21 CFR 1301.74(b). The regulation requires distributors to "design and operate a system to disclose to the registrant suspicious orders of controlled substances" and to inform DEA of suspicious orders when discovered.

DEA guidance published in December 2016 clarified that suspicious order monitoring systems must account for:

• Order size relative to historical patterns for the specific pharmacy
• Frequency of orders (particularly repeat orders within short timeframes)
• Geographic proximity to other high-volume purchasers
• Lack of legitimate medical purpose indicators (e.g., orders inconsistent with patient population demographics)

The SUPPORT Act, enacted October 24, 2018, strengthened DEA enforcement by requiring distributors to report suspicious orders not just to DEA, but also to notify the Administrator when they halt or decline a suspicious order. Failure to maintain effective monitoring systems is now explicitly grounds for registration revocation (21 U.S.C. 824(a)(4)).

Key Details of the Midwest Pharmaceutical Case

According to the U.S. Attorney's Office for the Southern District of Ohio, Chen received repeated red flags between June 2019 and August 2022:

• A Columbus pharmacy increased oxycodone 30mg orders by 847% over a six-month period
• A Cincinnati pharmacy ordered hydrocodone in quantities exceeding the combined patient population of its ZIP code by 300%
• Internal compliance staff flagged 14 pharmacies for irregular ordering patterns; Chen overrode suspension recommendations in 11 cases

Chen instructed staff to "process orders unless there's a legal hold" and directed the compliance team to avoid documenting concerns in writing. When DEA issued an administrative subpoena in February 2022, investigators found Chen had deleted email threads with compliance officers discussing specific pharmacies.

The prosecution presented testimony from a pharmacy owner who admitted purchasing controlled substances from Midwest Pharmaceutical specifically because "they didn't ask questions." The pharmacy lost its DEA registration in 2021 after state board investigation.

Chen was convicted on three counts:

1. Conspiracy to distribute controlled substances (21 U.S.C. 846)
2. Distribution of controlled substances (21 U.S.C. 841(a)(1))
3. Money laundering (18 U.S.C. 1956)

Midwest Pharmaceutical Distributors LLC was separately fined $4.2 million and agreed to a five-year compliance monitoring agreement with DEA. The company's DEA registration was not revoked but remains under probationary status.

Compliance Implications for Wholesale Drug Distributors

This case establishes three enforcement principles for wholesale drug distributor compliance violations:

Executive personal liability is enforceable. The SUPPORT Act removed ambiguity about whether "responsible corporate officers" could face criminal charges for compliance failures. Chen's conviction did not require proof he personally handled distribution logistics — only that he had authority over compliance systems and knowingly failed to maintain them.

Suspicious order monitoring is not optional. The prosecution emphasized Chen's active suppression of the monitoring system, not merely inadequate procedures. Distributors must document order review processes, maintain written policies for escalation, and retain records of declined orders. "We flag it but management overrides" is not a defense — it is evidence of criminal intent.

DEA data requests are preservation triggers. Chen's deletion of compliance emails became a separate obstruction charge. Distributors receiving DEA administrative subpoenas, inspection notices, or informal inquiry letters must immediately implement litigation holds on all controlled substance transaction records, compliance communications, and order review documentation.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration — a baseline requirement under 21 U.S.C. 360 for any distributor handling prescription drugs, including controlled substances. However, FDA registration does not verify DEA registration status or controlled substance handling authorization. DEA registration data is not yet included in ColdChainCheck compliance scores, as DEA does not currently participate in public data access programs comparable to FDA's Registration and Listing Database.

The average compliance score in ColdChainCheck's directory is 51/100, placing the industry median in the "Fair" tier. This score reflects verified signals across state licensure, NABP accreditation, FDA registration, and enforcement history — but does not capture controlled substance compliance posture. Only 63 entities in the directory hold NABP accreditation (formerly VAWD), which includes audited verification of inventory controls and order monitoring procedures. NABP-accredited distributors are statistically less likely to appear in DEA enforcement actions, though accreditation does not replace DEA-specific compliance obligations.

ColdChainCheck tracks 73 entities with at least one FDA recall on record. Recall history does not correlate directly with controlled substance violations, but it signals potential gaps in quality systems and documentation practices — both relevant to the Chen case, where prosecutors highlighted failures to maintain written compliance records.

Operational Response for QA and Compliance Teams

For companies evaluating trading partners:

• Use ColdChainCheck's directory to verify baseline FDA registration and state licensure for distributors in your supply chain. Cross-reference entity names against DEA's Diversion Control Division public database (separate manual lookup required).
• Prioritize NABP-accredited distributors when sourcing controlled substances. Filter the directory by "NABP Accreditation" status to identify the 63 verified entities.
• Document your due diligence process. Midwest Pharmaceutical's compliance monitoring agreement now requires written justification for every new pharmacy relationship. Apply the same standard to your distributor relationships.

For wholesale drug distributors handling controlled substances:

• Review your suspicious order monitoring system documentation. If your procedures are undocumented or rely on informal escalation, you are exposed to the same liability Chen faced.
• Audit override authority. If sales leadership can bypass compliance holds without written justification, implement immediate process changes. The prosecution's evidence centered on Chen's email directive to "process orders unless there's a legal hold."
• Implement automated litigation holds. Any communication from DEA — including informal phone inquiries — should trigger preservation of all controlled substance transaction records for the past 24 months.

ColdChainCheck's regulatory guides provide additional coverage of DEA distributor requirements, NABP accreditation standards, and state-level controlled substance licensing. Compliance scores will be updated to reflect DEA registration data once public access is available through the Resource Data Access (RDA) program.

Disclaimer: This article is informational only and does not constitute legal advice. Companies should consult qualified legal counsel regarding DEA compliance obligations and controlled substance distribution requirements.